Epidemiological data show that the prevalence of type 2 diabetes in adults in China is as high as 9.7%, and the prevention and treatment of diabetes has become an important issue of public health in China. Defective pancreatic β-cell function and insulin resistance are the main pathological basis of type 2 diabetes, and how to reverse or repair pancreatic β-cell function and reduce insulin resistance has been a hot spot in type 2 diabetes research. Traditional stepwise glucose-lowering drug regimens have not been effective in stopping the decline of pancreatic islet β-cell function, and the United Kingdom Prospective Diabetes Study (UKPDS) has shown that by the time diabetes is diagnosed, more than half of the islet function has been lost, and it will decrease at a rate of 4-5% per year for about 5 years. After about 5 years, only 25% of islet function is preserved, and after 10 years, islet function is almost completely exhausted. In 1997, Ilkova H et al. first used continuous subcutaneous insulin infusion (CSII) in 13 newly diagnosed type 2 diabetic patients. They found that 2 weeks of intensive insulin therapy resulted in more than 6 months of glycemic control after discontinuation of the drug in 9 patients treated with diet and exercise alone, demonstrating that intensive insulin therapy for primary diagnosis of type 2 diabetes can induce clinical remission (stable glycemic control with diet and exercise therapy alone) for a considerable period of time; in 2004 Ryan EA et al. used CSII in 16 patients with newly diagnosed type 2 diabetes. In a multicenter, randomized, controlled, prospective clinical study conducted by Professor Weng Jianping et al. in China, short-term (2-5 weeks) intensive insulin therapy (CSII, MDI) and conventional oral hypoglycemic drug therapy (CSII, MDI) were observed. The results showed that among 382 newly diagnosed type 2 diabetic patients, the insulin intensive therapy group could achieve glycemic control in a shorter period of time compared with the oral hypoglycemic therapy group, and the clinical remission rates at 1 year follow-up were 51.1% in the CSII group and 44.9% in the MDI group. The OAD group was 26.7%. The study showed that for patients with primary type 2 diabetes mellitus with significant hyperglycemia, short-term insulin intensive therapy has the effect of rapid and stable glycemic control and significant improvement of pancreatic β-cell function, and some patients even completely restored insulin first-phase secretion, alleviated glucose and lipotoxicity, and improved islet cord sensitivity through the modulation of adipocytokines and inflammatory pathways and endoplasmic reticulum stress response, so that type 2 diabetes mellitus was clinically remitted in The clinical remission of type 2 diabetes for a considerable period of time while maintaining the blood glucose standard and staying in the early stage of diabetes. There are also some domestic studies on the intensive treatment of primary type 2 diabetes mellitus with traditional Chinese medicine combined with insulin, such as Yu Hong observed 48 cases of yin deficiency dry heat type primary type 2 diabetes mellitus, randomly divided into insulin group and traditional Chinese medicine combined with insulin group, the results showed that there was no significant difference in glycemic control between the two groups, but there were statistically significant differences in pancreatic β-cell function index and major symptom scores in the traditional Chinese medicine combined with insulin treatment group compared with the insulin treatment group (P